European Organisation for Research and Treatment of Cancer (EORTC)

The aims of the European Organisation for Research and Treatment of Cancer (EORTC) are to develop, conduct, coordinate, and stimulate laboratory and clinical research in Europe to improve the management of cancer and related problems by increasing survival but also patients’ quality of life. Extensive and comprehensive research in this wide field is often beyond the means of individualEuropean laboratories and hospitals, and can best be accomplished through the multidisciplinary, multinational efforts of basic research scientists and clinicians from the European continent. During the last few years, numerous innovative agents have been discovered as a result of tremendous development in the understanding of the molecular basis of cancer. Further clinical progress in cancer
treatment will be accomplished mainly through the conduct of translational research projects, efficient drug development and the execution of large, prospective, randomized, multicenter cancer clinical trials. EORTC promotes multidisciplinary cancer research in Europe and is linked to other leading biomedical research organizations around the world. EORTC has the aim to facilitate the passage of experimental discoveries into state-of-the-art treatment by keeping to a minimum the time lapse between the discovery of new anti-cancer agents and the implementation of their therapeutic benefit for patients with cancer. The ultimate goal of the EORTC is to improve the standard of cancer treatment in Europe, through the development of innovative drugs, and to establish more effective therapeutic strategies, using drugs already commercially available, or surgery and radiotherapy.

Contact Details: Avenue E. Mounier, 83/11 Brussels 1200 Belgium Tel: Fax: Email: WWW: www.eortc.be/

Recent Publications by European Organisation for Research and Treatment of Cancer (EORTC):
Biomarkers for malignant pleural mesothelioma: current status. Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor...	25th February, 2009	European Organisation for Research and Treatment of Cancer (EORTC),	Mol Diagn Ther. 2008;12(6):375-90. doi: 10.2165/1250444-200812060-00004.
International perspective on health-related quality-of-life research in cancer clinical trials: the European Organisation for Research and Treatment of Cancer experience. Over recent decades, health-related quality of life (HRQOL) research has...	6th December, 2007	European Organisation for Research and Treatment of Cancer (EORTC) Quality	J Clin Oncol. 2007 Nov 10;25(32):5082-6. DOI Direct Link
Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma. PURPOSE: Whether salvage therapy in patients with advanced aggressive...	7th November, 2007	European Organisation for Research and Treatment of Cancer (EORTC) Data	Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1168-77. Epub 2006 Aug 2. DOI Direct Link
Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. BACKGROUND: The aim of this prognostic factor analysis was to investigate...	3rd February, 2007	European Organisation for Research and Treatment of Cancer (EORTC), EORTC	Ann Oncol. 2006 Nov;17(11):1698-704. Epub 2006 Sep 12. DOI Direct Link
Methodological quality of patient-reported outcome research was low in complementary and alternative medicine in oncology. OBJECTIVE: To evaluate the methodological robustness of patient-reported...	21st December, 2006	European Organisation for Research and Treatment of Cancer (EORTC), EORTC	J Clin Epidemiol. 2006 Dec;59(12):1257-65. Epub 2006 Jul 3. DOI Direct Link
→View more European Organisation for Research and Treatment of Cancer (EORTC) research publications.

Press Releases on European Organisation for Research and Treatment of Cancer (EORTC):
Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium	11th September, 2008	Ardea Biosciences, Inc.	SAN DIEGO, Sept. 11 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that preclinical data will be presented on the Company's lead mitogen-activated ERK kinase
SuperGen Reports 2008 Second Quarter Financial Results	4th August, 2008	SuperGen, Inc.	DUBLIN, Calif., Aug. 4 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid
Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival	11th July, 2008	Schering-Plough	KENILWORTH, N.J., July 11 /PRNewswire-FirstCall/ -- Today, Schering-Plough (NYSE: SGP) and the EORTC announced that long-term treatment with pegylated interferon alfa-2b in stage III melanoma
Biotech Tracker News - Onyx’s Raf Inhibitor Shows Promise	1st September, 2002	Biotracker	Biotech Tracker News - Onyx’s Raf Inhibitor Shows Promise November

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 277 times since April 2007, the link to the organisation's website has been followed 53 times

Recent Search Terms used to find this page: Eortc europe 2009 | EORTC 2002 | EORTC pharmaecutical company | .

Search for more companies in Brussels

Search for more companies in

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for European Organisation for Research and Treatment of Cancer (EORTC)